Search results
Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). [1] . There is some evidence it may improve some ME/CFS symptoms. [1] It is an immunomodulatory double-stranded RNA drug similar to the prototypical RNA poly I:C.
Ampligen (Rintatolimod) is a Broadly Applicable Immune Therapy 3 • Ampligen is a broadly applicable immune therapy that has the potential to be used in a wide range of indications • Generally well-tolerated with over 100,000 IV doses in humans • Ampligen has Orphan Drug Status in Myalgic Encephalomyelitis/Chronic
As of 2016, it has been approved for severe ME/CFS in Argentina. That same year it was approved for an Early Access Program in EU and Turkey. The US Food and Drug Administration (FDA) have not approved Ampligen for wide use in ME/CFS.
24 gru 2012 · Ampligen, an immunomodulatory double stranded RNA drug developed by Hemispherx Biopharma in Philadelphia, PA, has been shown to help a subset of patients with CFS by reducing symptoms.
Ampligen (Rintatolimod) Mechanism of Action • Ampligen is a synthetic dsRNA and activator of TLR3 • Ampligen is unique amongst TLR agonists in its mechanism of action, specificity and safety profile Only known TLR agonist to avoid the systemic inflammatory MyD88 pathway used by all other TLRs. Action is through the TRIF adaptor pathway.
Ampligen ® Has Significant Opportunity Across High-Value Multiple Disease Areas ~100,000 IV doses in humans, generally well-tolerated Positive Phase 3 data generated in U.S. in treatment of ME/CFS. Data from multiple in-vitro, preclinical (animal) models and clinical studies provide encouraging results in a range of potential clinical uses
27 lis 2012 · Ampligen® [ polyI:polyC12U] is a mismatched double-stranded RNA that acts by inducing interferon production (immunomodulator) and by activating an intracellular enzyme (RNase-L) against viral RNA transcripts (antiviral).
